Study: Novel heart failure drug shows big promise - KXNet.com - Bismarck/Minot/Williston/Dickinson-KXNEWS,ND

Study: Novel heart failure drug shows big promise

Posted: Updated:
(AP Photo/Rafiq Maqbool, File). FILE - In this April 1, 2013 file photo, a dove flies near the logo of Novartis India Limited at their head office in Mumbai, India. (AP Photo/Rafiq Maqbool, File). FILE - In this April 1, 2013 file photo, a dove flies near the logo of Novartis India Limited at their head office in Mumbai, India.
By MARILYNN MARCHIONE
AP Chief Medical Writer

A new study reports one of the biggest potential advances against heart failure in more than a decade - a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20 percent.

Doctors say the Novartis drug - which doesn't have a name yet - seems like one of those rare, breakthrough therapies that could quickly change care for more than half of the 6 million Americans and 24 million people worldwide with heart failure.

"This is a new day" for patients, said Dr. Clyde Yancy, cardiology chief at Northwestern University in Chicago and a former American Heart Association president.

"It's been at least a decade since we've had a breakthrough of this magnitude," said Yancy, who had no role in the study.

It involved nearly 8,500 people in 47 countries and was the largest experiment ever done in heart failure. It was paid for, designed and partly run by Novartis, based in Basel, Switzerland. Independent monitors stopped the study in April, seven months earlier than planned, when it was clear the drug was better than an older one that is standard now.

During the 27-month study, the Novartis drug cut the chances of dying of heart-related causes by 20 percent and for any reason by 16 percent, compared to the older drug. It also reduced the risk of being hospitalized for heart failure by 21 percent.

"We are really excited," said one study leader, Dr. Milton Packer of UT Southwestern Medical Center in Dallas. The benefit "exceeded our original expectations."

Results were disclosed Saturday at a European Society of Cardiology conference in Barcelona and published online by the New England Journal of Medicine.

Novartis will seek approval for the drug - for now called LCZ696 - by the end of this year in the United States and early next year in Europe

Heart failure is the top reason older people are hospitalized, and a leading cause of death. It develops when the heart muscle weakens over time and can no longer pump effectively, often because of damage from a heart attack. Fluid can back up into the lungs and leave people gasping for breath.

The people in this study were already taking three to five medicines to control the condition. One medicine often used is an ACE inhibitor, and the study tested one of these - enalapril, sold as Vasotec and in generic form - against the Novartis drug.

The new drug is a twice-a-day pill combination of two medicines that block the effects of substances that harm the heart while also preserving ones that help protect it. One of the medicines also dilates blood vessels and allows the heart to pump more effectively.

In the study, 26.5 percent on the older drug, enalapril, died of heart-related causes or were hospitalized for heart failure versus less than 22 percent of those on the Novartis drug. Quality of life also was better with the experimental drug.

"We now have a way of stabilizing and managing their disease which is better than what we could offer them before," Packer said.

The new drug also seemed safe - reassuring because safety concerns doomed a couple of other promising-looking treatments over the last decade. There were more cases of too-low blood pressure and non-serious swelling beneath the skin with the Novartis drug, but more kidney problems, excess potassium in the blood and cough with the older drug. More people on the older treatment dropped out of the study than those on the new one.

About 32 people would need to be treated with the new drug to prevent one death from heart-related causes.

"That's a favorable number," said Dr. Joseph G. Rogers, a Duke University cardiologist with no role in the study. He said the benefits were big enough that "I would switch people over" as soon as the drug is available.

The drug "may well represent a new threshold of hope" for patients, Dr. Mariell Jessup, heart failure chief at the University of Pennsylvania, wrote in a commentary in the journal. It may help "a wide spectrum of patients, even those who are currently receiving the best possible therapy."

___

Online:

Heart failure information: http://tinyurl.com/2avrgpo

and http://tinyurl.com/ltakeyb

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

  • U.S. & World NewsMore>>

  • Miss New York chosen as Miss America 2015

    Miss New York chosen as Miss America 2015

    Sunday, September 14 2014 11:31 PM EDT2014-09-15 03:31:02 GMT
    After months of bad news including casino closings and thousands of laid-off workers, Atlantic City is in for some positive publicity.
    Miss New York Kira Kazantsev was named the new Miss America Sunday night, marking the third year in a row that a contestant from her state has walked away with the crown in the nationally televised pageant.
  • Obama condemns beheading of Briton by extremists

    Obama condemns beheading of Briton by extremists

    Sunday, September 14 2014 10:20 PM EDT2014-09-15 02:20:21 GMT
    President Barack Obama is condemning as a "barbaric murder" the slaying of British aid worker David Haines by Islamic State extremists.
    President Barack Obama on Saturday condemned as a "barbaric murder" the slaying of British aid worker David Haines by Islamic State extremists.
  • Police: Trooper hurt in ambush conscious, talking

    Police: Trooper hurt in ambush conscious, talking

    Sunday, September 14 2014 9:40 PM EDT2014-09-15 01:40:42 GMT
    With the deadly ambush on a state police barracks in the Pocono Mountains, law enforcement in eastern Pennsylvania went on high alert and officers from throughout the region, including New York and New Jersey,...
    A Pennsylvania state trooper who was injured when a gunman ambushed him and killed another trooper outside a police barracks is conscious and talking for the first time since he underwent surgery, a spokesman said Sunday.
Powered by WorldNow
General information or questions:
kxinfo@kxnet.com

News:
Bismarck:
Phone: 701-223-9197
News Fax: 701-223-1985

News:
Minot:
Phone: 701-852-2104
News Fax: 701-838-1050
All content © Copyright 2000 - 2014 WorldNow and KXNET. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.